Quantcast
Last updated on April 18, 2014 at 21:21 EDT

Latest Haemophilia Stories

2014-01-13 16:26:08

FLINT, Mich., Jan. 13, 2014 /PRNewswire-iReach/ -- Diplomat, the country's largest independent specialty pharmacy, announced today it has acquired American Homecare Federation (AHF), Inc. AHF is an Enfield, Conn.-based provider of hemophilia pharmacy services serving the homecare needs of the bleeding disorders community throughout the U.S. The announcement was made by Diplomat CEO and co-founder, Phil Hagerman, R.Ph. "Diplomat is pleased to expand our footprint in the hemophilia...

2013-12-23 16:23:07

PLAINSBORO, N.J., Dec. 23, 2013 /PRNewswire/ -- Novo Nordisk today announced the US Food and Drug Administration (FDA) has approved TRETTEN(®) (Coagulation Factor XIII A-Subunit [Recombinant]) for the routine prophylaxis of bleeding in people with congenital factor XIII (FXIII) A-subunit deficiency, a serious, rare bleeding disorder with limited treatment options. TRETTEN(®) is the only recombinant treatment for congenital FXIII A-subunit deficiency. TRETTEN(®) was proven safe and...

2013-12-20 08:26:00

PHILADELPHIA, Dec. 20, 2013 /PRNewswire/ -- Spark Therapeutics, a fully integrated, late-stage gene therapy company, announced today that President and Chief Executive Officer Jeffrey D. Marrazzo will present a company overview at the 32(nd) Annual J.P. Morgan Healthcare Conference. Marrazzo's presentation will highlight the company's progress in developing potentially curative, one-time gene therapies for the treatment of inherited blindness and hemophilia, and provide an overview of...

2013-12-09 08:25:55

Dr. High presents recent therapeutic successes for gene therapy as well as perceived hurdles to bringing potentially curative products to patients suffering from genetic diseases PHILADELPHIA, Dec. 9, 2013 /PRNewswire/ -- Spark Therapeutics, a fully integrated, late-stage gene therapy company, today announced that its co-founder and scientific advisor, Dr. Katherine A. High, accepted the E. Donnall Thomas Lecture Prize and presented a lecture on her career's work to develop novel genetic...

2013-12-03 08:31:26

Full article: http://bit.ly/EpiVax_Biotest DREIEICH, Germany and PROVIDENCE, R.I., Dec. 3, 2013 /PRNewswire/ -- Biotest AG, Dreieich, Germany and EpiVax, Inc., Providence, Rhode Island, USA are pleased to announce a new Collaborative Research Agreement. With this collaboration a novel, non-immunogenic Factor VIII (FVIII) should be developed. The coagulation factor VIII used for Hemophilia therapy will be altered in such a way that the immune system of the patients may not respond by...

2013-11-20 12:28:09

Washington, DC-Based National Hemophilia Foundation Chapter Takes Home Top Prize WHIPPANY, N.J., Nov. 20, 2013 /PRNewswire/ -- Bayer HealthCare and the National Hemophilia Foundation (NHF) today announced the successful conclusion of the third annual Virtual Walk for Hemophilia, an engaging, online contest designed to raise awareness and funds for those living with bleeding disorders. The Virtual Walk for Hemophilia (www.walkforhemophilia.com) employs a website where visitors can...

2013-11-13 12:27:00

DEERFIELD, Ill., Nov. 13, 2013 /PRNewswire/ -- Baxter International Inc. today announced it has completed enrollment in its Phase III clinical trial of BAX 855, an investigational extended half-life, recombinant factor VIII (rFVIII) treatment for hemophilia A. The ongoing trial is aimed at assessing the efficacy of the compound in reducing annualized bleed rates (ABR) in both prophylaxis and on-demand treatment schedules, and will also evaluate its safety and pharmacokinetic profile....

2013-10-24 04:21:25

DSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE Euronext: DSM KON), announced today that it has signed a manufacturing agreement for commercial supply with Sanquin Blood Supply Foundation, The Netherlands. PARSIPPANY, N.J., Oct. 24, 2013 /PRNewswire/ -- The agreement covers the commercial manufacture of a monoclonal antibody used for the recovery and purification of coagulation factor IX from human blood. Factor IX is a protein...

2013-10-22 08:33:03

Fully Integrated Gene Therapy Company with Deep Clinical Pipeline Spun out of The Children's Hospital of Philadelphia PHILADELPHIA, Oct. 22, 2013 /PRNewswire/ -- Spark Therapeutics, a new, fully integrated company developing gene-based medicines for a wide range of debilitating diseases, announced today it has launched with a $50 million capital commitment from The Children's Hospital of Philadelphia (CHOP) to advance and commercialize multiple ongoing programs with clinical proof of...

2013-10-11 08:24:11

Integration of medical and pharmacy data shows pharmacy benefit preferred for clotting factor management ST. PAUL, Minn., Oct. 11, 2013 /PRNewswire/ -- Treatment costs for the congenital bleeding disorders, hemophilia and von Willebrand's Disease (vWD) can vary substantially, from as little as $1,139 per year to more than $3 million per year, according to a study by pharmacy benefit manager Prime Therapeutics LLC (Prime). Prime will be presenting the study at the Academy of Managed...